Li Z, Liu S, Liu D, Yang K, Xiong J, Fang Z
J Exp Clin Cancer Res. 2025; 44(1):84.
PMID: 40038799
PMC: 11881293.
DOI: 10.1186/s13046-025-03318-6.
Shang K, He Q, Xu X, Luo X, Zhao C, Liu L
Ther Clin Risk Manag. 2025; 21():15-25.
PMID: 39802955
PMC: 11721357.
DOI: 10.2147/TCRM.S489899.
Iwama S, Kobayashi T, Arima H
Nat Rev Endocrinol. 2025; .
PMID: 39779950
DOI: 10.1038/s41574-024-01077-6.
Guo G, Jing Z, Dou W, Wang G, Dang J, Li Y
Front Immunol. 2025; 15:1495460.
PMID: 39763663
PMC: 11700968.
DOI: 10.3389/fimmu.2024.1495460.
Iwamoto Y, Kimura T, Dan K, Iwamoto H, Sanada J, Fushimi Y
Sci Rep. 2025; 15(1):390.
PMID: 39747534
PMC: 11695621.
DOI: 10.1038/s41598-024-84488-9.
Immune checkpoint inhibitors and endocrinopathies in pediatric brain tumor patients.
Westermann C, Davidson T, Waters K, Margol A, Cheung C
J Pediatr Endocrinol Metab. 2024; 38(1):58-64.
PMID: 39680426
PMC: 11832116.
DOI: 10.1515/jpem-2024-0243.
A Case of Uveitis and Hypothyroidism Following Pembrolizumab Therapy in a Patient With Plantar Malignant Melanoma.
Sugino H, Kitamura M, Yoshioka M, Saito-Sasaki N, Sawada Y
Cureus. 2024; 16(11):e73530.
PMID: 39669853
PMC: 11636581.
DOI: 10.7759/cureus.73530.
Development of pituitary dysfunction and destructive thyroiditis is associated with better survival in non-small cell lung cancer patients treated with programmed cell death-1 inhibitors: a prospective study with immortal time bias correction.
Suzuki K, Kobayashi T, Izuchi T, Otake K, Ando M, Handa T
Front Endocrinol (Lausanne). 2024; 15:1490042.
PMID: 39574956
PMC: 11578695.
DOI: 10.3389/fendo.2024.1490042.
Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal.
Li X, Song Z, Chen Y, Wu J, Jiang D, Zhang Z
Cancer Immunol Immunother. 2024; 74(1):2.
PMID: 39487885
PMC: 11531454.
DOI: 10.1007/s00262-024-03816-0.
Enhancing cancer immunotherapy: Nanotechnology-mediated immunotherapy overcoming immunosuppression.
Chen Y, Zhou Q, Jia Z, Cheng N, Zhang S, Chen W
Acta Pharm Sin B. 2024; 14(9):3834-3854.
PMID: 39309502
PMC: 11413684.
DOI: 10.1016/j.apsb.2024.05.032.
Concurrent Gitelman Syndrome and Hyperthyroidism: Diagnostic Challenges in a 51-Year-Old Patient.
Zhang Y, Yu H, Li J, Cheng L
Am J Case Rep. 2024; 25:e944909.
PMID: 39210578
PMC: 11370197.
DOI: 10.12659/AJCR.944909.
Is F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons.
Karlsen W, Akily L, Mierzejewska M, Teodorczyk J, Bandura A, Zaucha R
Cancers (Basel). 2024; 16(11).
PMID: 38893111
PMC: 11171385.
DOI: 10.3390/cancers16111990.
Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study.
Kobayashi T, Iwama S, Yamagami A, Izuchi T, Suzuki K, Otake K
Cancer Immunol Immunother. 2024; 73(8):146.
PMID: 38833157
PMC: 11150211.
DOI: 10.1007/s00262-024-03733-2.
Immune-related thyroid dysfunction in patients with non-small cell lung cancer.
Cai C, Zhou S, Qu J, Zhou J
J Thorac Dis. 2024; 16(1):253-263.
PMID: 38410546
PMC: 10894408.
DOI: 10.21037/jtd-23-1092.
Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment: Relationship Between Antibodies and Severity of Thyroid Dysfunction.
Miguelez Gonzalez M, Galdon Sanz-Pastor A, Gomez R, Torrecilla N, Munoz Moreno D, Gonzalez Fernandez L
Endocr Metab Immune Disord Drug Targets. 2024; 24(14):1628-1639.
PMID: 38362680
DOI: 10.2174/0118715303280679240206100137.
Inflammatory Profile Assessment in a Highly Selected Athyreotic Population Undergoing Controlled and Standardized Hypothyroidism.
Piticchio T, Savarino F, Volpe S, Prinzi A, Costanzo G, Gamarra E
Biomedicines. 2024; 12(1).
PMID: 38275410
PMC: 10813236.
DOI: 10.3390/biomedicines12010239.
Mechanisms and biomarkers of immune-related adverse events in gastric cancer.
Ding P, Liu P, Meng L, Zhao Q
Eur J Med Res. 2023; 28(1):492.
PMID: 37936161
PMC: 10631148.
DOI: 10.1186/s40001-023-01365-3.
Hyperthyroidism: A Review.
Lee S, Pearce E
JAMA. 2023; 330(15):1472-1483.
PMID: 37847271
PMC: 10873132.
DOI: 10.1001/jama.2023.19052.
Reduced Tumor Size of Untreated Papillary Thyroid Carcinoma After Immune Checkpoint Inhibitor-Induced Thyroiditis.
Chen D, Lenz H, Lechner M, Angell T
AACE Clin Case Rep. 2023; 9(5):162-165.
PMID: 37736314
PMC: 10509378.
DOI: 10.1016/j.aace.2023.05.009.
Toxicity spectrum and risk factors for chemo-immunotherapy in locally advanced or metastatic lung cancer.
Li J, Shi W, Xiong J, Huang Y, He Y, Zhou Y
Clin Exp Immunol. 2023; 214(2):162-169.
PMID: 37696500
PMC: 10714187.
DOI: 10.1093/cei/uxad105.